ABSTRACT: Non-inflammatory skin involvement in breast cancer, histologically proven but without the clinical and histological T4 category features Uwe Gueth, MD 1 *, Edward Wight, MD 1, Andreas Schoetzau, MS 2, Igor Langer, MD 3, Holger Dieterich, MD 4, Christoph Rochlitz, MD 5, Linda Herberich, MD 1, Wolfgang Holzgreve, MD 1, Gad Singer, MD 6 1Department of Gynecology and Obstetrics, University Hospital Basel (UHB), Spitalstrasse, Basel, Switzerland 2JPS Institute for Biomathematics, Malzgasse, Basel, Switzerland 3Department of Surgery, UHB, Spitalstrasse, Basel, Switzerland 4Women's Hospital and Breast Center Rheinfelden, Therese-Herzog-Weg, Rheinfelden, Germany 5Department of Medical Oncology, UHB, Petersgraben, Basel, Switzerland 6University of Basel, Institute of Pathology, Schönbeinstrasse, Basel, Switzerland email: Uwe Gueth (ugueth@uhbs.ch) *Correspondence to Uwe Gueth, Department of Gynecology and Obstetrics, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland. Fax: 0041-61-2659037. Background: The study evaluates characteristics and prognostic significance of breast cancer with histologically proven non-inflammatory skin involvement but without the clinical and histological features that are mandatory for inclusion in the T4 category. Methods: We compared retrospectively the clinical course of 55 patients with this clinico-pathologic entity to the outcome of a control group of 309 consecutive patients with tumors of the same size but without skin involvement. The median follow-up time was 6.6 years in the study and 8.4 years in the control group. Two subsets were analyzed: (A) 1.1-2.0 cm (T1c); (B) 2.1-5.0 cm (T2). Results: The distribution of TNM stages within Study Group A was: Stage I: 28.6%, Stage II: 61.9%, Stage III: 9.5%. The distribution within Study Group B was: Stage II: 67.7%, Stage III: 23.5%, and Stage IV: 8.8%. Differences in disease-specific survival (DSS) between study and control groups were not significant. In multivariate analysis, skin involvement was not a significant variable, while lymph node involvement was found to be significant for worse outcome (Group A: HR = 3.99 [1.33-12.05], P = 0.014; Group B: HR = 2.37 [1.37-4.08], P = 0.002). Conclusion: Breast carcinomas with histologically proven skin involvement without the clinical and histological correlate are a heterogeneous group of cases, but the majority of the patients have Stage I/II disease. While lymph node involvement had a most significant effect on DSS, skin involvement was not a significant prognostic factor. Physicians must be aware of this clinico-pathologic entity in order not to misclassify these cases as T4 and consider them falsely as being locally advanced breast cancer. Journal of Surgical Oncology Volume 95, Issue 4 , Pages 291 - 297 10.1002/jso.20660 Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.